Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-center, Dose Escalation Phase I Study of Single Agent RO5520985 (Vanucizumab), and in Combination With Atezolizumab, Administered as an Intravenous Infusion in Patients With Locally Advanced or Metastatic Solid Tumors
Conditions
Interventions
Atezolizumab [TECENTRIQ]
Vanucizumab
Locations
14
Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Institut Bergonie; Oncologie
Bordeaux, France
Centre Francois Baclesse; Oncologie
Caen, France
Centre Leon Berard; Departement Oncologie Medicale
Lyon, France
Institut Curie; Oncologie Medicale
Paris, France
Start Date
October 31, 2012
Primary Completion Date
December 2, 2016
Completion Date
March 12, 2018
Last Updated
October 5, 2018
NCT00026884
NCT07169851
NCT07159659
NCT07213804
NCT07191730
NCT07481851
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions